Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms, Castration-Resistant 1

Interventions

Specimen Handling 51pembrolizumab 46Magnetic Resonance Spectroscopy 38Biopsy 37Cyclophosphamide 34fludarabine 29Cetuximab 20Cisplatin 19Carboplatin 19Radiotherapy 16Bevacizumab 16atezolizumab 15Radiation 15venetoclax 14Nivolumab 14Fluorouracil 14fludarabine phosphate 13Leucovorin 13Gemcitabine 13Temozolomide 11Pemetrexed 11Oxaliplatin 11Cytarabine 11Paclitaxel 10Irinotecan 10Ipilimumab 10130-nm albumin-bound paclitaxel 10Prednisone 9Immunoglobulin G 9Fulvestrant 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Pioglitazone × 30 days × Clear all
NCT02592317 2026-06-05

A Study to Evaluate the Effect of Multiple Doses of JNJ-56021927 on the Pharmacokinetics of Multiple Cytochrome P450 and Transporter Substrates in Participants With Castration-Resistant Prostate Cancer

Aragon Pharmaceuticals, Inc.

Phase 1 Active not recruiting
23 enrolled
Genitourinary

Prostatic Neoplasms, Castration-Resistant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡